News

Preoperative organ dysfunction worsens SAVR outcomes


 

EXPERT ANALYSIS FROM THE CARDIOVASCULAR CONFERENCE AT SNOWMASS

SNOWMASS, COLO. – The presence of preoperative dysfunction in more than any one of four key organ systems profoundly reduces survival in patients undergoing surgical aortic valve replacement, a study showed.

"If you have two or more dysfunctional organ systems, you really need to think about what you’re doing for this patient. At 5 years, only about 40% of these patients are alive. It makes a lot of sense to me to say that if you have a patient with severe COPD [chronic obstructive pulmonary disease] and renal dysfunction, that patient should probably never get a surgical valve," Dr. Vinod H. Thourani said at the Annual Cardiovascular Conference at Snowmass.

Dr. Vinod H. Thourani

In a retrospective analysis of a registry with prospectively entered data, 29% of 1,759 patients who underwent surgical aortic valve replacement (SAVR) with or without coronary artery bypass grafting at Emory University during 2002-2010 had preoperative dysfunction of one or more of four organ systems under scrutiny. Eighty-five patients had severe COPD, as defined by a forced expiratory volume in 1 second (FEV1) that was less than 50% of predicted, 140 had chronic renal failure, 149 had a prior stroke, and 241 had heart failure with a left ventricular ejection less than 35%.

Patients with chronic renal failure had far and away the worst 30-day and long-term outcomes. Half were dead within 3 years. The 7-year survival rate was just 11.7%.

The second-worst outcomes were seen in patients with severe COPD preoperatively. Their 7-year survival rate was 30.8%.

"Anyone with an FEV1 below about 40% becomes a higher-risk surgical candidate; think instead of TAVR [transcatheter aortic valve replacement],"advised Dr. Thourani of the division of cardiothoracic surgery at Emory University, Atlanta.

In contrast, outcomes in patients with either heart failure or prior stroke "were not that bad," he said, pointing to 7-year survival rates of 55.9% and 48.6%, respectively.

Ninety-five patients (5.4%) in this recently published study (Ann. Thorac. Surg. 2013;95:838-45) had more than one dysfunctional organ system prior to SAVR. Median survival in patients without dysfunction in any of the four organ systems was 8.2 years and counting. With one dysfunctional organ, it was still good at 7.2 years. However, with two dysfunctional organ systems, the median survival dropped precipitously to 4.1 years. With three dysfunctional organ systems, it was 5.9 years.

Dr. Thourini serves as a consultant to Edwards Lifesciences, Sorin, and St. Jude Medical.

bjancin@frontlinemedcom.com

Recommended Reading

Medical conferences going digital
MDedge Family Medicine
Limited neonatal benefit from later delivery in congenital heart disease
MDedge Family Medicine
Gastric bypass associated with greatest improvement in cardiac risk factors
MDedge Family Medicine
CORAL: No added benefit with renal stenting vs. medication alone
MDedge Family Medicine
Noninvasive coronary test accurate for lesion-specific ischemia
MDedge Family Medicine
Novel Watchman antistroke device backed as warfarin equivalent
MDedge Family Medicine
Thrombosis precautions in IBD not met in two-thirds of high-risk cases
MDedge Family Medicine
Higher PCI risk in diabetes not due to insulin
MDedge Family Medicine
CoreValve holds size advantage for U.S. TAVR
MDedge Family Medicine
WOEST results guide antithrombotic therapy in PCI
MDedge Family Medicine